Chronotropic and inotropic effects of bradykinin on isolated, blood-perfused canine atrium. 1980

M Kobayashi, and Y Furukawa, and S Chiba

Effects of bradykinin on SA node pacemaker activity and atrial contractility were studied, using isolated, blood-perfused dog atrium preparations. Bradykinin (0.1--100 micrograms) caused a slightly but consistently positive chronotropic action, although it did not produce a consistent inotropic action. When successive doses of bradykinin were given in a short period, these preparations displayed tachphylaxis. Bradykinin-induced action was not suppressed by a potent beta-adrenoceptor blocking agent, carteolol. In addition, kallikrein (0.1--3 units), was administered into the sinus node artery to investigate the effect of endogenous kinins. Kallikrein had no effect on SA node pacemaker activity nor atrial contractility at any examined doses. On the other hand, a kallikrein inhibitor, aprotinin, induced dose-relatedly a negative inotropic and chronotropic effect at a dose range from 100 to 3,000 units. These negative actions of aprotinin were not blocked by an adequate dose of atropine. From these results, it is concluded that bradykinin has a slight direct positive chronotropic effect, and that aprotinin has direct negative inotropic and chronotropic effects in the isolated, blood-perfused canine atrium in a wide dose range.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007611 Aprotinin A single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. It is an inhibitor of proteolytic enzymes including CHYMOTRYPSIN; KALLIKREIN; PLASMIN; and TRYPSIN. It is used in the treatment of HEMORRHAGE associated with raised plasma concentrations of plasmin. It is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with EXTRACORPOREAL CIRCULATION. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995) BPTI, Basic Pancreatic Trypsin Inhibitor,Basic Pancreatic Trypsin Inhibitor,Bovine Kunitz Pancreatic Trypsin Inhibitor,Kallikrein-Trypsin Inactivator,Kunitz Pancreatic Trypsin Inhibitor,Trypsin Inhibitor, Basic, Pancreatic,Trypsin Inhibitor, Kunitz, Pancreatic,Antilysin,Bovine Pancreatic Trypsin Inhibitor,Contrical,Contrykal,Dilmintal,Iniprol,Kontrikal,Kontrykal,Pulmin,Traskolan,Trasylol,Zymofren,Inactivator, Kallikrein-Trypsin,Kallikrein Trypsin Inactivator
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D002354 Carteolol A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol Hydrochloride,Carteolol Monohydrochloride,OPC-1085,Hydrochloride, Carteolol,Monohydrochloride, Carteolol,OPC 1085,OPC1085
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006325 Heart Atria The chambers of the heart, to which the BLOOD returns from the circulation. Heart Atrium,Left Atrium,Right Atrium,Atria, Heart,Atrium, Heart,Atrium, Left,Atrium, Right
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse

Related Publications

M Kobayashi, and Y Furukawa, and S Chiba
August 1985, Japanese journal of pharmacology,
M Kobayashi, and Y Furukawa, and S Chiba
March 1977, Japanese heart journal,
M Kobayashi, and Y Furukawa, and S Chiba
July 1976, European journal of pharmacology,
M Kobayashi, and Y Furukawa, and S Chiba
January 1975, The Tohoku journal of experimental medicine,
M Kobayashi, and Y Furukawa, and S Chiba
October 1989, Japanese journal of pharmacology,
M Kobayashi, and Y Furukawa, and S Chiba
January 1977, Archives internationales de pharmacodynamie et de therapie,
M Kobayashi, and Y Furukawa, and S Chiba
January 1978, Clinical and experimental pharmacology & physiology,
M Kobayashi, and Y Furukawa, and S Chiba
January 1976, Recent advances in studies on cardiac structure and metabolism,
M Kobayashi, and Y Furukawa, and S Chiba
May 1976, The Tohoku journal of experimental medicine,
Copied contents to your clipboard!